Scalper1 News
Biotech Endocyte (ECYT) and its big-pharma partner Merck (MRK) got a double dose of good news on their cancer drug vintafolide Friday, more than doubling Endocyte’s stock on the stock market today. First, the European Medicines Agency’s advisory committee recommended conditional approval of vintafolide, branded Vynfinit, along with two companion imaging agents for treatment of ovarian cancer. The imaging agents are used to identify cancers that Scalper1 News
Scalper1 News